pubmed: erectile dysfunction...
NCBI: db=pubmed; Term=Erectile dysfunction and Stem Cell Therapy
NCBI pubmed
  • 2014 Update Of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research To Clinical Management.
    Related Articles

    2014 Update Of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research To Clinical Management.

    Curr Pharm Des. 2014 Oct 29;

    Authors: Gur S, Sikka SC, Kadowitz PJ, Silberstein J, Hellstrom WJ

    Abstract
    Radical prostatectomy (RP) is the most commonly employed curative intervention for the treatment of prostate cancer. However, due to the proximity of the cavernous nerves (CN) to the prostate, RP results in transient and/often permanent erectile dysfunction (ED). While the prevention of traction injuries during the RP is critical for the preservation of erectile function, several preclinical studies have demonstrated the beneficial effects of neuroprotective (or neuroregenerative) agents in mitigating neuronal injuries sustained during RP. The maintenance or restoration of erectile function after injury may be enhanced in the postoperative period by the stimulation of neurogenesis to protect and restore injured nerves from further deterioration. The present review aims to evaluate and summarize research of these treatment strategies as published in the National Library of Medicine (Pubmed) from 2000 to 2014. The keywords used for the search were ED, RP, CN injury, immunophilin ligands, neurotrophins and phosphodiesterase (PDE)-5 inhibitors, and animal models. Current guidelines for treatment targeting CN recovery recommend the use of immunophilin ligands, neurotrophins, brain-derived neurotrophic factor, glial cell-line derived neurotrophic factor, sonic hedgehog (Shh), Rho-kinase, PDE-5 inhibitors, erythropoietin (EPO), hyperbaric oxygen therapy, super enzyme gene therapy, stem cells, and triiodothyronine (T3) therapy. Additionally, this review identifies remaining gaps in general knowledge and recent updates recognizing the need for further preclinical and clinical trials.

    PMID: 25354178 [PubMed - as supplied by publisher]

  • Rat cavernous nerve reconstruction with CD133+ cells derived from human bone marrow.
    Related Articles

    Rat cavernous nerve reconstruction with CD133+ cells derived from human bone marrow.

    J Sex Med. 2014 May;11(5):1148-58

    Authors: Miyamoto K, Inoue S, Kobayashi K, Kajiwara M, Teishima J, Matsubara A

    Abstract
    INTRODUCTION: Erectile dysfunction remains a major complication after surgery of pelvic organs, especially after radical prostatectomy.
    AIM: The aim of this study was to assess the effect of endothelial progenitor cells on the regeneration of cavernous nerves in a rat injury model.
    METHODS: A 2 mm length of the right and left cavernous nerves of 8-week-old male nude rats were excised. Alginate gel sponge sheets supplemented with 1 × 10(4) CD133+ cells derived from human bone marrow were then placed over the gaps on both sides (CD group). The same experiments were performed on sham-operated rats (SH group), rats with only the nerve excision (EX group), and rats with alginate gel sheets placed on the injured nerves (AL group).
    MAIN OUTCOME MEASURES: Immunofluorescence staining and molecular evaluation were performed 4 days later. Functional and histological evaluations were performed 12 weeks later.
    RESULTS: The intracavernous pressure elicited by electrical stimulation and the neuronal nitric oxide synthase-positive area in surrounding tissues of the prostate was significantly greater in the CD group. Immunofluorescence microscopy showed that CD133+ cells were assimilated as vascular endothelial cells, and the real-time polymerase chain reaction showed upregulation of nerve growth factor and vascular endothelial growth factor in the alginate gel sponge sheets of the CD group.
    CONCLUSIONS: Transplantation of CD133+ cells accelerated the functional and histological recovery in this cavernous nerve injury model, and the recovery mechanism is thought to be angiogenesis and upregulation of growth factors. CD133+ cells could be an optional treatment for cavernous nerve injury after prostatectomy in clinical settings.

    PMID: 24576198 [PubMed - indexed for MEDLINE]

pubmed: erectile dysfunction...
NCBI: db=pubmed; Term=Erectile dysfunction and Stem Cell Treatment
NCBI pubmed
  • 2014 Update Of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research To Clinical Management.
    Related Articles

    2014 Update Of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research To Clinical Management.

    Curr Pharm Des. 2014 Oct 29;

    Authors: Gur S, Sikka SC, Kadowitz PJ, Silberstein J, Hellstrom WJ

    Abstract
    Radical prostatectomy (RP) is the most commonly employed curative intervention for the treatment of prostate cancer. However, due to the proximity of the cavernous nerves (CN) to the prostate, RP results in transient and/often permanent erectile dysfunction (ED). While the prevention of traction injuries during the RP is critical for the preservation of erectile function, several preclinical studies have demonstrated the beneficial effects of neuroprotective (or neuroregenerative) agents in mitigating neuronal injuries sustained during RP. The maintenance or restoration of erectile function after injury may be enhanced in the postoperative period by the stimulation of neurogenesis to protect and restore injured nerves from further deterioration. The present review aims to evaluate and summarize research of these treatment strategies as published in the National Library of Medicine (Pubmed) from 2000 to 2014. The keywords used for the search were ED, RP, CN injury, immunophilin ligands, neurotrophins and phosphodiesterase (PDE)-5 inhibitors, and animal models. Current guidelines for treatment targeting CN recovery recommend the use of immunophilin ligands, neurotrophins, brain-derived neurotrophic factor, glial cell-line derived neurotrophic factor, sonic hedgehog (Shh), Rho-kinase, PDE-5 inhibitors, erythropoietin (EPO), hyperbaric oxygen therapy, super enzyme gene therapy, stem cells, and triiodothyronine (T3) therapy. Additionally, this review identifies remaining gaps in general knowledge and recent updates recognizing the need for further preclinical and clinical trials.

    PMID: 25354178 [PubMed - as supplied by publisher]

  • Rat cavernous nerve reconstruction with CD133+ cells derived from human bone marrow.
    Related Articles

    Rat cavernous nerve reconstruction with CD133+ cells derived from human bone marrow.

    J Sex Med. 2014 May;11(5):1148-58

    Authors: Miyamoto K, Inoue S, Kobayashi K, Kajiwara M, Teishima J, Matsubara A

    Abstract
    INTRODUCTION: Erectile dysfunction remains a major complication after surgery of pelvic organs, especially after radical prostatectomy.
    AIM: The aim of this study was to assess the effect of endothelial progenitor cells on the regeneration of cavernous nerves in a rat injury model.
    METHODS: A 2 mm length of the right and left cavernous nerves of 8-week-old male nude rats were excised. Alginate gel sponge sheets supplemented with 1 × 10(4) CD133+ cells derived from human bone marrow were then placed over the gaps on both sides (CD group). The same experiments were performed on sham-operated rats (SH group), rats with only the nerve excision (EX group), and rats with alginate gel sheets placed on the injured nerves (AL group).
    MAIN OUTCOME MEASURES: Immunofluorescence staining and molecular evaluation were performed 4 days later. Functional and histological evaluations were performed 12 weeks later.
    RESULTS: The intracavernous pressure elicited by electrical stimulation and the neuronal nitric oxide synthase-positive area in surrounding tissues of the prostate was significantly greater in the CD group. Immunofluorescence microscopy showed that CD133+ cells were assimilated as vascular endothelial cells, and the real-time polymerase chain reaction showed upregulation of nerve growth factor and vascular endothelial growth factor in the alginate gel sponge sheets of the CD group.
    CONCLUSIONS: Transplantation of CD133+ cells accelerated the functional and histological recovery in this cavernous nerve injury model, and the recovery mechanism is thought to be angiogenesis and upregulation of growth factors. CD133+ cells could be an optional treatment for cavernous nerve injury after prostatectomy in clinical settings.

    PMID: 24576198 [PubMed - indexed for MEDLINE]